252 related articles for article (PubMed ID: 37122737)
1. Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?
Noto A; Cassin R; Mattiello V; Bortolotti M; Reda G; Barcellini W
Front Immunol; 2023; 14():1062376. PubMed ID: 37122737
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
Carrillo de Albornoz S; Chai KL; Higgins AM; Petrie D; Wood EM; McQuilten ZK
Int J Technol Assess Health Care; 2024 May; 40(1):e32. PubMed ID: 38751245
[TBL] [Abstract][Full Text] [Related]
4. A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.
Lachance S; Christofides AL; Lee JK; Sehn LH; Ritchie BC; Shustik C; Stewart DA; Toze CL; Haddad E; Vinh DC
Curr Oncol; 2016 Feb; 23(1):42-51. PubMed ID: 26966403
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics.
Innocenti I; Tomasso A; Benintende G; Autore F; Fresa A; Vuono F; Stirparo L; Galli E; D'Arena G; Sorà F; Efremov D; Laurenti L
Hematol Oncol; 2022 Aug; 40(3):469-474. PubMed ID: 35076123
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection.
Keegan A; Dennington PM; Dhondy N; Mulligan SP
Eur J Haematol; 2022 Jun; 108(6):460-468. PubMed ID: 35152500
[TBL] [Abstract][Full Text] [Related]
7. The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID).
Ameratunga R; Ahn Y; Steele R; Woon ST
Front Immunol; 2019; 10():1541. PubMed ID: 31379811
[No Abstract] [Full Text] [Related]
8. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
[TBL] [Abstract][Full Text] [Related]
9. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
Ohmoto A; Fuji S; Shultes KC; Savani BN; Einsele H
Bone Marrow Transplant; 2022 Jun; 57(6):874-880. PubMed ID: 35440805
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
11. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.
Spadaro G; Pecoraro A; De Renzo A; Della Pepa R; Genovese A
Clin Immunol; 2016 May; 166-167():103-4. PubMed ID: 27063866
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.
Carrillo de Albornoz S; Higgins AM; Petrie D; Irving A; Fanning L; Weinkove R; Crispin P; Dendle C; Gilbertson M; Johnston A; Keegan A; Pepperell D; Pullon H; Reynolds J; van Tonder T; Trotman J; Waters N; Wellard C; Weston H; Morrissey CO; Wood EM; McQuilten ZK
Blood Adv; 2024 May; 8(9):2259-2267. PubMed ID: 38484199
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.
Colado A; Elías EE; Sarapura Martínez VJ; Cordini G; Morande P; Bezares F; Giordano M; Gamberale R; Borge M
Sci Rep; 2021 Jun; 11(1):12926. PubMed ID: 34155276
[TBL] [Abstract][Full Text] [Related]
14. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China.
Ye C; Liu J; Song X; Zheng S; Liu J
Medicine (Baltimore); 2021 Jan; 100(3):e23935. PubMed ID: 33545966
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.
Compagno N; Cinetto F; Semenzato G; Agostini C
Haematologica; 2014 Jun; 99(6):1101-6. PubMed ID: 24682509
[TBL] [Abstract][Full Text] [Related]
16. [Intravenous and subcutaneous immunoglobulin therapy].
Thon V
Epidemiol Mikrobiol Imunol; 2013 Jul; 62(2):64-73. PubMed ID: 23964967
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.
Link H; Kerkmann M; Holtmann L; ;
Support Care Cancer; 2022 Jun; 30(6):5187-5200. PubMed ID: 35257229
[TBL] [Abstract][Full Text] [Related]
18. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry.
Abadeh A; Shehadeh S; Betschel S; Waserman S; Cameron DW; Cowan J
PLoS One; 2023; 18(11):e0294408. PubMed ID: 37971974
[TBL] [Abstract][Full Text] [Related]
20. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
Front Immunol; 2021; 12():670547. PubMed ID: 34012453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
